Perrigo Cuts Annual Guidance, This OTC Drug Firm Also Reports Mixed Q3 Earnings

  • Grand News Network
  • November 7, 2023

Perrigo Company PLC (NYSE: PRGO) reported third-quarter sales of $1.12 billion, up 2.2% Y/Y, missing the consensus of $1.20 billion, driven primarily by the acquisition of the Gateway infant formula facility and the U.S. and Canadian Good Start infant formula brand. 

The company reported adjusted EPS of $0.64 compared to $0.56 a year ago, beating the consensus of $0.61.

Also Read: First Birth Control Pill For OTC Use In US Lands ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner